Glancy Prongay Wolke & Rotter LLP reminded investors of separate lead-plaintiff deadlines in proposed securities class actions involving PROCEPT BioRobotics Corporation and Replimune Group, Inc. PROCEPT investors who acquired securities from February 28, 2024, through February 25, 2026, may seek appointment by September 22, 2026, after disclosures involving weaker handpiece sales, excess inventory and a discontinued bulk-purchase discount program. Replimune investors who acquired securities from October 20, 2025, through April 10, 2026, may seek appointment by October 5, 2026, after the U.S. Food and Drug Administration rejected the company’s Biologics License Application for RP1 combined with nivolumab. PROCEPT shares fell 13.35%, 9.74% and 15.12% after the cited disclosures, while Replimune shares fell 19.46% on April 10 and another 64.29% on April 13. Investors in either proposed class do not need to take action to remain absent members and may retain counsel or take no action.